Dementia syndromes: evaluation and treatment

References

• American Psychiatric Association. Dementia of the Alzheimer’s type. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. American Psychiatric Association, Washington DC, USA (1994).
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical disgnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group. Neurology34, 939–944 (1985).
   Google Scholar
• Hebert L, Scherr P, Bienias J, Bennett D, Evans D. Alzheimer disease in the US population: prevalence estimates using the census. Arch. Neurol.60(8), 1119–1122 (2003).
   PubMed Web of Science ®Google Scholar
• Biller J. Practical Neurology (2nd Edition). Lippincott Williams & Wilkins, PA, USA (2002).
   Google Scholar
• Folstein M, Folstein S, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res.12(3), 189–198 (1975).
   PubMed Web of Science ®Google Scholar
• Blessed G, Tomlinson B, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry114, 797–811 (1968).
   PubMed Web of Science ®Google Scholar
• Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer’s disease. Am. J. Psychiatry141(11), 1356–1364 (1984).
   PubMed Web of Science ®Google Scholar
• McGurn B, Starr J, Topfer J et al. Pronunciation of irregular words is preserved in dementia, validating premorbid IQ estimation. Neurology62(7), 1184–1186 (2004).
   PubMed Web of Science ®Google Scholar
• Barrett A, Eslinger P, Ballentine N, Heilman K. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology64(4), 693–699 (2005).
   PubMed Web of Science ®Google Scholar
• Crum R, Anthony J, Bassett S, Folstein M. Population-based norms for the mini-mental state examination by age and educational level. JAMA269(18), 2386–2391 (1993).
   PubMed Web of Science ®Google Scholar
• Grigoletto F, Zappala G, Anderson D, Lebowitz B. Norms for the mini-mental state examination in a healthy population. Neurology53(2), 315–320 (1999).
   PubMed Web of Science ®Google Scholar
• Borson S, Scanlan J, Chen P, Ganguli M. The Mini-cog as a screen for dementia: validation in a population-based sample. J. Am. Geriatr. Soc.51(10), 1451–1454 (2003).
   PubMed Web of Science ®Google Scholar
• Weytingh M, Bossuyt P, Crevel H. Reversible dementia: more than 10% or less than 1%? A quantitative review. J. Neurol.242(7), 466–471 (1995).
   PubMed Web of Science ®Google Scholar
• Knopman D, DeKosky S, Cummings J. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56(9), 1143–1153 (2001).
   PubMed Web of Science ®Google Scholar
• Sunderland T, Linker G, Mirza N, Putnam K. Decreased β-amyloid 42 and increase tau levels in cerebrospinal fluid of patients with Alzheimer’s disease. JAMA289(16), 2094–2103 (2003).
   PubMed Web of Science ®Google Scholar
• Clark C, Xie S, Chittams J et al. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autospy-confirmed dementia diagnoses? Arch. Neurol.60(12), 1696–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch. Neurol.58(3), 373–379 (2001).
   PubMed Web of Science ®Google Scholar
• Silverman D, Small G, Chang C et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA286, 2120–2127 (2001).
   PubMed Web of Science ®Google Scholar
• Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease: FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging32, 486–510 (2005).
   PubMed Web of Science ®Google Scholar
• Lim A, Tsuang D, Kukull W et al. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based series. J. Am. Geriatr. Soc.47, 564–569 (1999).
   PubMed Web of Science ®Google Scholar
• Zamrini E, DeSanti S, Tolar M. Imaging is superior to cognitive testing for early diagnosis of Alzheimer’s disease. Neurobiol. Aging25, 685–691 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen R, Stevens J, Ganguli M, Tangalos E, Cummings J, DeKosky S. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56, 1133–1142 (2001).
   PubMed Web of Science ®Google Scholar
• Bozoki A, Giodani B, Heidebrink J, Berent S, Foster N. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch. Neurol.58, 411–416 (2001).
   PubMed Web of Science ®Google Scholar
• Morris J, Storandt M, Miller J et al. Mild cognitive impairment represents early-stage Alzheimer’s disease. Arch. Neurol.58(3), 397–405 (2001).
   PubMed Web of Science ®Google Scholar
• Bennett D, Wilson R, Schneider J et al. Natural history of mild cognitive impairment in older patients. Neurology59(2), 198–205 (2002).
   PubMed Web of Science ®Google Scholar
• Birks B, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst. Rev.3, CD006104 (2006).
   Google Scholar
• Petersen R, Thomas R, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352(23), 2379–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Salloway S, Ferris S, Kluger A et al. Efficacy of donepezil in mild cognitive impariment: a randomized placebo-controlled trial. Neurology63(4), 651–657 (2004).
   PubMed Web of Science ®Google Scholar
• Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment. Br. Med. J.330, 276 (2005).
   PubMed Web of Science ®Google Scholar
• Perl D. Neuropathology of Alzheimer’s disease and related disorders. Neurol. Clin.18(4), 847–864 (2000).
   PubMed Web of Science ®Google Scholar
• Tiraboschi P, Hansen L, Thal L, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology62, 1984–1989 (2004).
   PubMed Web of Science ®Google Scholar
• Gearing M, Mirra S, Hedreen J, Sumi S, Hansen L, Heyman A. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology45(3), 461–466 (1995).
   PubMed Web of Science ®Google Scholar
• Kukull W, Larson E, Reifler B, Lampe T, Yerby M, Hughes J. The validity of 3 clinical diagnostic criteria for Alzheimer’s disease. Neurology40(9), 1364–1369 (1990).
   PubMed Web of Science ®Google Scholar
• Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology51(6), 1546–1554 (1998).
   PubMed Web of Science ®Google Scholar
• McKeith L, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology47(5), 1113–1124 (1996).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen J, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson’s disease. A community based, prospective study. Neurology56(6), 730–736 (2001).
   PubMed Web of Science ®Google Scholar
• Emre M. Dementia in Parkinson’s disease: cause and treatment. Curr. Opin. Neurol.17(4), 399–404 (2004).
   PubMedGoogle Scholar
• Jankovic J, Tolosa E, Jankovic JJ TE (Eds). Parkinson’s Disease and Movement Disorders (4th Edition). Lippincott Williams & Wilkins Philadelphia, USA (2002).
   Google Scholar
• No authors listed. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J. Neurol. Psychiatry57, 416 (1994).
   PubMed Web of Science ®Google Scholar
• Huey E, Putnam K, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology66(1), 17–22 (2006).
   PubMed Web of Science ®Google Scholar
• Hodges J, Putnam K, Grafman J. Clinicopathological correlates in frontotemporal dementia. Ann. Neurol.56, 399–406 (2006).
   Google Scholar
• McKhann G, Albert M, Grossman M, Miller B, Dickson D, Trojanowski J. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s disease. Arch. Neurol.58(11), 1803–1809 (2001).
   PubMed Web of Science ®Google Scholar
• Chui H, Mack W, Jackson E et al. Clinical criteria for the diagnosis of vascular dementia. A multicenter study of comparability and interrater reliability. Arch. Neurol.57(2), 191–196 (2000).
   PubMedGoogle Scholar
• Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. Stroke31(12), 2952–2957 (2000).
   PubMed Web of Science ®Google Scholar
• Snowdon D, Greiner L, Mortimer J, Riley K, Greiner P, Markesbery W. Brain infarction and the clinical expression of Alzheimer disease: the Nun study. JAMA277, 813–817 (1997).
   PubMed Web of Science ®Google Scholar
• Honig L, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology64, 494–500 (2005).
   PubMed Web of Science ®Google Scholar
• Luchsinger J, Reitz C, Honig L, Tang M, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incipient Alzheimer disease. Neurology65, 545–551 (2005).
   PubMed Web of Science ®Google Scholar
• Massoud F, Devi G, Stern Y et al. A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia. Arch. Neurol.56, 1368–1373 (1999).
   PubMedGoogle Scholar
• Lim A, Tsuang D, Kukull W et al. Cliniconeuropathological correlation of Alzheimer’s disease in a community-based series. J. Am. Geriatr. Soc.47, 564–569 (1999).
   PubMed Web of Science ®Google Scholar
• Langa K, Foster N, Larson E. Mixed dementia: emerging concepts and therapeutic implications. JAMA292(23), 2901–2908 (2004).
   PubMed Web of Science ®Google Scholar
• Clarfield A. The reversible dementias: do they reverse? Ann. Intern. Med.109, 476 (1988).
   PubMed Web of Science ®Google Scholar
• Clarfield A. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch. Intern. Med.163(18), 2219–2229 (2003).
   PubMedGoogle Scholar
• Hejl A, Hogh P, Waldemar G. Potentially reversible conditions in consecutive memory clinic patients. J. Neurol. Neurosurg. Psychiatry73(4), 390–394 (2002).
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Kumar A. Clinically significant nonmajor depression: old concepts, new insights. Am. J. Geriatr. Psychiatry10(3), 239–255 (2002).
   PubMed Web of Science ®Google Scholar
• Georgieff N, Dominey P, Michel F, Marie-Cardine M, Dalery J. Anomia in major depressive state. Psychiatry Res.77(3), 197–208 (1998).
   PubMed Web of Science ®Google Scholar
• Berger A, Fratiglioni L, Forsell Y, Winblad B, Backman L. The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology53(9), 1998–2002 (1999).
   PubMed Web of Science ®Google Scholar
• Baik H, Russell R. Vitamin B12 deficiency in the elderly. Annu. Rev. Nutr.19, 357–377 (1999).
   PubMed Web of Science ®Google Scholar
• Dharmarajan T, Norkus E. Approaches to vitamin B12 deficiency: early treatment may prevent devastating complications. Postgrad. Med.110(1), 99–105 (2001).
   PubMed Web of Science ®Google Scholar
• Wang H, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B12 and folate in relation to the development of Alzheimer’s disease. Neurology56(9), 1188–1194 (2001).
   PubMed Web of Science ®Google Scholar
• Butler C, Vidal-Alabal J, Cannings-John R et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systemic review of randomized controlled trials. Fam. Pract.23, 279–285 (2006).
   PubMedGoogle Scholar
• Diez J. Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J. Gerontol. A. Biol. Sci. Med. Sci.57(5), M315–M320 (2002).
   Web of Science ®Google Scholar
• Wardle C, Squire C. Pitfalls in the use of thyrotropin concentration as a first-line thyroid-function test. Lancet357(9261), 1013–1014 (2001).
   PubMedGoogle Scholar
• Pepersack T, Garbusinski J, Robberecht J, Beyer I, Willems D, Fuss M. Clinical relevance of thiamine status amongst hospitalized elderly patients. Gerontology45(2), 96–101 (1999).
   PubMed Web of Science ®Google Scholar
• Menninger J. Assessment and treatment of alcoholism and substance-related disorders in the elderly. Bull. Menninger Clin.66(2), 166–183 (2002).
   PubMed Web of Science ®Google Scholar
• Seshardri S. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer’s disease? J. Alzh. Disease9, 393–398 (2006).
   PubMedGoogle Scholar
• McCracken C, Hudson P, Ellis R, McCaddon A. Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Aging Study. Am. J. Clin. Nutrition84, 1406–1411 (2006).
   PubMedGoogle Scholar
• Merritt’s Neurology (10th Edition). Lippincott Williams & Wilkins, New York, USA.
   Google Scholar
• Bernstein R, Dowd C, Gress D. Rapidly reversible dementia. Lancet361(9355), 392 (2003).
   PubMedGoogle Scholar
• Gultekin S, Rosenfeld MR, Voltz R, Eichen J, Posen J, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain123(7), 1481–1494 (2000).
   PubMed Web of Science ®Google Scholar
• Doody R, Stevens J, Beck C. Practice parameter: management of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56(9), 1154–1166 (2001).
   PubMed Web of Science ®Google Scholar
• Sano M, Ernesto C, Thomas R et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. New Engl. J. Med.336(17), 1216–1222 (1997).
   PubMed Web of Science ®Google Scholar
• Birks J, Flicker L. Selegiline for Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD000442 (2003).
   Google Scholar
• Malouf R, Grimley E. The effect of vitamin B6 on cognition. Cochrane Database Syst. Rev.4, CD004393 (2003).
   Google Scholar
• Malouf M, Grimley E, Areosa S. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst. Rev.4, CD004514 (2003).
   Google Scholar
• Andersen K, Launer L, Ott A, Hoes A, Breteler M, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk of Alzheimer’s disease? The Rotterdam study. Neurology45(8), 1441–1445 (1995).
   PubMed Web of Science ®Google Scholar
• Kawas C, Resnick S, Morrison A et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease. Lancet48(6), 1517–1521 (1997).
   Google Scholar
• Tang M, Jacobs D, Stern Y et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet348(9025), 429–432 (1996).
   PubMed Web of Science ®Google Scholar
• Yaffe K, Sawaya G, Leiberburg I, Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA279(9), 688–695 (1998).
   PubMed Web of Science ®Google Scholar
• LeBlanc E, Janowski J, Chan B, Nelson H. Hormone replacement therapy and cognition. Systematic review and meta-analysis. JAMA285(11), 1489–1499 (2001).
   PubMed Web of Science ®Google Scholar
• Shumaker S, Legault C, Thal L et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA289(20), 2651–2662 (2003).
   PubMed Web of Science ®Google Scholar
• Shumaker S, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA291(24), 2947–2958 (2004).
   PubMed Web of Science ®Google Scholar
• Espeland M, Rapp S, Shumaker S, Brunner R, Manson J, Sherwin B et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA291(24), 2959–2968 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider L. Estrogen and dementia: insights from the Women’s Health Initiative Memory Study. JAMA291(24), 3005–3007 (2004).
   PubMedGoogle Scholar
• Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst. Rev.3, CD003799 (2002).
   Google Scholar
• Janowsky J. The role of androgens in cognition and brain aging in men. Neuroscience138, 1015–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J. Clin. Endocrinol. Metab.84, 3681–3685 (1999).
   PubMed Web of Science ®Google Scholar
• Gruenewald D, Matsumoto A. Testosterone supplementation therapy for older men: potential benefits and risks. J. Am. Geriatr. Soc.51, 101–115 (2003).
   PubMed Web of Science ®Google Scholar
• Almeida O, Flicker L. Testosterone and dementia: too much ado about too little data. J. Br. Menopause Soc.9, 107–110 (2003).
   PubMedGoogle Scholar
• Skoog I, Gustafson D. Update on hypertension and Alzheimer’s disease. Neurol. Res.6, 605–611 (2006).
   Google Scholar
• McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst. Rev.2, CD004034 (2006).
   Google Scholar
• Dufouil C, Richard F, Fievet N et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia. Neurology64, 1531–1538 (2005).
   PubMed Web of Science ®Google Scholar
• Tan Z, Seshadri S, Beiser A et al. Plasma total cholesterol level as a risk factor for Alzheimer’s disease: the Framingham study. Arch. Intern. Med.163, 1053–1057 (2003).
   PubMed Web of Science ®Google Scholar
• Frears E, Stephens D, Walters C, Davies H, Austen B. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport10, 1699–1705 (1999).
   PubMed Web of Science ®Google Scholar
• Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA98, 5856–5861 (2001).
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia G, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol.57, 1439–1443 (2000).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw G, Murphy M et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur. J. Pharmacol.545, 51–64 (2006).
   PubMed Web of Science ®Google Scholar
• Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The gingko biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur. J. Neurosci.12, 1882–1890 (2000).
   Google Scholar
• Yao Z, Drieu K, Papadopoulos V. The gingko biloba extract EGb 761 rescues the PC12 neuronal cells from β-amyloid induced cell death by inhibiting the formation of β-amyloid derived diffusable neurotoxic ligands. Brain Res.889, 181–190 (2004).
   Google Scholar
• Oken B, Storzbach D, Kaye J. The efficacy of ginko biloba on cognitive function in Alzheimer’s disease. Arch. Neurol.55, 1409–1415 (1998).
   PubMed Web of Science ®Google Scholar
• Rogers S, Farlow M, Doody R et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. N. Engl. J. Med.336, 1216–1222 (1998).
   Google Scholar
• Birks J, Grimley E, Dongen MV. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev.4, CD003120 (2002).
   Google Scholar
• Ganguli M, Chandra V, Kamboh M et al. Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US cross-national dementia study. Arch. Neurol.57, 824–830 (2000).
   PubMed Web of Science ®Google Scholar
• Lim G, Chu T, Yang F, Beech W, Frautschy S, Cole G. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer’s transgenic mouse. J. Neurosci.21, 8370–8377 (2001).
   PubMed Web of Science ®Google Scholar
• Sun A, Simonyi A, Sun G. The “French Paradox”and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med.32, 314–318 (2002).
   PubMed Web of Science ®Google Scholar
• Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology59, 1313–1319 (2002).
   PubMed Web of Science ®Google Scholar
• Lindsay J, Laurin D, Verreault R et al. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol.156, 445–453 (2002).
   PubMed Web of Science ®Google Scholar
• Reid M, Van Ness PV, Hawkins K, Towle V, Concato J, Guo Z. Light to moderate alcohol consumption is associated with better cognitive function among older male veterans receiving primary care. J. Geriatr. Psychiatry Neurol.19, 98–105 (2006).
   PubMed Web of Science ®Google Scholar
• Stampfer M, Kang J, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N. Engl. J. Med.352(3), 245–253 (2005).
   PubMed Web of Science ®Google Scholar
• Chick J, Smith M, Engleman H et al. Magnetic resonance imaging of the brain in alcoholics: cerebral atrophy, lifetime alcohol consumption, and cognitive deficits. Alcohol Clin. Exp. Res.13, 512–518 (1989).
   PubMedGoogle Scholar
• Schaefer E, Bongard V, Beiser A et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease. Arch. Neurol.63, 1545–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Conquer J, Tierney M, Zecevic J, Bettger W, Fisher R. Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids35, 1305–1312 (2000).
   PubMed Web of Science ®Google Scholar
• Morris M, Evans D, Tangney C et al. Fish consumption and cognitive decline with age in a large community study. Arch. Neurol.62, 1849–1853 (2005).
   PubMedGoogle Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400, 173–177 (1999).
   PubMed Web of Science ®Google Scholar
• Bayer A, Bullock R, Jones R et al. Evaluation of the safety and immunogenicity of synthetic AB42 (AN1792) in patients with AD. Neurology64, 94–101 (2004).
   Google Scholar
• Holtzman D. Role of apoE/A-β interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy. J. Mol. Neurosci.17, 147–155 (2001).
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD005593 (2006).
   Google Scholar
• Qizilbash N, Birks J, Arrieta JL, Lewington S, Szeto S. Tacrine for Alzheimer’s disease. Cochrane Database Syst. Rev.3, CD000202 (2000).
   Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev.1, CD001747 (2006).
   Google Scholar
• Lancelot E, Beal M. Glutamate toxicity in chronic neurodegenerative disease. Prog. Brain Res.116, 331–347 (1998).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H. Memantine in moderate-to-severe Alzheimer’s disease. New Engl. J. Med.348(14), 1333–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H. A 24-week open-label extension study of memantine in moderate to severe Alzheimer’s disease. Arch. Neurol.63(1), 49–54 (2006).
   PubMed Web of Science ®Google Scholar
• Areosa S, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst. Rev.2, CD003154 (2005).
   Google Scholar
• Tariot P, Farlow M, Grossberg G, Graham S, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer’s disese already receiving donepezil: a randomized controlled trial. JAMA291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Borenstein J, Salob S et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J. Clin. Psychiatry48, 9–15 (1987).
   PubMed Web of Science ®Google Scholar
• Deyn PD, Rabheru K, Rasmussen A et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology53, 946–955 (1999).
   PubMedGoogle Scholar
• Anonymous. Practice guideline for treatment of patients with Alzheimer’s disease and other dementias of late life. Am. J. Psychiatry154, 1–39 (1997).
   PubMed Web of Science ®Google Scholar
• Sink K, Holden K, Yaffe K. Parmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA293(5), 596–608 (2005).
   PubMed Web of Science ®Google Scholar
• Lee P, Gill S, Freedman M et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia. Br. Med. J.329, 75 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider L, Dagerman K, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA294, 1934 (2005).
   PubMed Web of Science ®Google Scholar
• Jones P, Barnes T, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia. Arch. Gen. Psychiatry63, 1079–1087 (2006).
   PubMed Web of Science ®Google Scholar
• Lieberman J, Stroup S, McEvoy J et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353, 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Shumaker S, Legault C, Coker L. Behavior-based interventions to enhance cognitive functioning and independence in older adults. JAMA296, 2852–2854 (2006).
   PubMed Web of Science ®Google Scholar
• Colcombe S, Kramer A. Fitness effects on the cognitive function of older adults. Psychol. Sci.14, 125–130 (2003).
   PubMed Web of Science ®Google Scholar
• Heyn P, Abreu B, Ottenbacker K. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch. Phys. Med. Rehabil.8, 1694–1704 (2004).
   Google Scholar
• Kramer A, Hahn S, Gopher D. Task coordination and aging: explorations of executive control processes in the task switching paradigm. Acta Psychol. (Amst.)101, 339–378 (1999).
   PubMed Web of Science ®Google Scholar
• Willis S, Tennstedt S, Marsiske M, Ball K, Elias J, Koepke K et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA296, 2805–2814 (2006).
   PubMed Web of Science ®Google Scholar